News & Updates

Switching from other anti-VEGF* agents to brolucizumab only helps improve visual acuity and reduces disease activity in patients with neovascular (wet) age-related macular degeneration (nAMD)

Treatment with memantine significantly reduces hair pulling and skin-picking symptoms when compared with placebo, demonstrating relatively high efficacy and tolerability, reports a study.

Treatment with remdesivir reduced mortality in a large cohort of hospitalized patients requiring high-flow oxygen, according to a study presented at ECCMID 2023.

Individuals with germline genetic alterations, particularly the BRCA1/2 pathogenic/likely pathogenic variant (PV/LPV), do not appear to experience any significant increase in post-COVID vaccination side effects, as reported in a study from Singapore.

In the management of advanced cancers, physicians and their patients may prefer treatment with nivolumab 3 mg/kg biweekly, nivolumab 240 mg weekly, or nivolumab 3 mg/kg plus ipilimumab 1 mg/kg triweekly due to their relatively low risk of treatment-related adverse events (TRAEs), treatment discontinuation due to TRAEs (TDAE), and serious adverse events (SAEs), suggests a study.